Annual Report
Our report on activities & financial performance throughout the year.
You may request paper copies of these materials by email, online, or by dialing 866-648-8133.
Note: You must register to be eligible to participate in the meeting.
May 8, 2025
9:00 a.m. EDT
IN8bio was founded with the mission of developing next-generation cellular therapies for treating cancer. Dr. Lawrence Lamb, one the Company’s co-founders, is a leader in the field of gamma-delta T cells. During his postdoctoral fellowship in transplant medicine, he was the first to describe homeostatic reconstitution of gamma-delta T cells in patients who receive alpha-beta T cell depleted bone marrow grafts. Dr. Lamb also identified an association between gamma-delta T cell levels and disease-free survival in allogeneic bone marrow transplantation. This work formed the foundation of IN8bio’s focus on delivering gamma-delta therapeutics for the treatment of cancer. The Company is developing allogeneic, autologous and genetically modified gamma-delta T cell therapies. Dr. Lamb’s research has formed the basis for the company’s two Phase 1 clinical trials, one in newly-diagnosed Glioblastoma and one in leukemia and lymphoma patients undergoing hematopoietic stem cell transplant. Additionally, the Company is also continuing to explore the application of its technology in additional therapeutic combinations. IN8bio is located in New York City with its primary scientific operations in Birmingham, Alabama.
